Trial Profile
A Randomized, Parallel-Group, Open-Label Study to Evaluate the Absolute Bioavailability, Pharmacokinetics, Tolerability and Safety of a High Concentration Formulation of Belimumab (HGS1006), a Fully Human Monoclonal Anti-BLyS Antibody, Administered Subcutaneously to Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Belimumab (Primary) ; Belimumab (Primary)
- Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Lupus nephritis; Membranous glomerulonephritis; Myasthenia gravis; Myositis; Renal transplant rejection; Sjogren's syndrome; Systemic lupus erythematosus; Systemic scleroderma
- Focus Pharmacokinetics
- Sponsors Human Genome Sciences
- 08 Sep 2017 Results of pooled analysis assessing pharmacokinetics and pharmacodynamics of BEL114448, BEL116119, BEL112341 published in the Clinical Pharmacokinetics.
- 30 Jan 2013 Trial association changed from Human Genome Sciences to GlaxoSmithKline, as Human Genome Sciences acquired by GlaxoSmithKline.
- 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology Health Professionals.